Rosenberg Matthew Hamilton Buys 248 Shares of Boston Scientific Co. (NYSE:BSX)

Rosenberg Matthew Hamilton boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 15.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,820 shares of the medical equipment provider’s stock after acquiring an additional 248 shares during the period. Rosenberg Matthew Hamilton’s holdings in Boston Scientific were worth $163,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Traveka Wealth LLC lifted its holdings in shares of Boston Scientific by 6.4% during the 4th quarter. Traveka Wealth LLC now owns 3,444 shares of the medical equipment provider’s stock worth $308,000 after acquiring an additional 206 shares during the period. BCS Wealth Management acquired a new position in Boston Scientific in the fourth quarter worth about $388,000. PFW Advisors LLC bought a new position in Boston Scientific during the fourth quarter worth about $207,000. Marion Wealth Management acquired a new stake in Boston Scientific during the fourth quarter valued at approximately $202,000. Finally, Courier Capital LLC grew its stake in shares of Boston Scientific by 108.7% in the 4th quarter. Courier Capital LLC now owns 22,384 shares of the medical equipment provider’s stock valued at $1,999,000 after purchasing an additional 11,661 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of several recent analyst reports. Mizuho boosted their price target on Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Stifel Nicolaus upped their target price on shares of Boston Scientific from $85.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Citigroup increased their target price on shares of Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Sanford C. Bernstein boosted their price target on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Finally, Bank of America lifted their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Three investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $97.26.

Boston Scientific Price Performance

Shares of BSX stock opened at $94.78 on Tuesday. The firm’s 50 day moving average price is $90.16 and its two-hundred day moving average price is $84.02. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. Boston Scientific Co. has a 52-week low of $59.61 and a 52-week high of $97.13. The stock has a market cap of $139.69 billion, a PE ratio of 78.33, a PEG ratio of 2.67 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same period last year, the company earned $0.50 EPS. The firm’s revenue was up 19.3% on a year-over-year basis. As a group, analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current year.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the transaction, the executive vice president now directly owns 978 shares of the company’s stock, valued at $87,306.06. This trade represents a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,877 shares of the company’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the sale, the director now owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,989 shares of company stock worth $2,702,261. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.